Kenvue Inc. (NYSE:KVUE) Shares Sold by Financiere des Professionnels Fonds d investissement inc.

Financiere des Professionnels Fonds d investissement inc. trimmed its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 4.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 407,091 shares of the company's stock after selling 16,904 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.'s holdings in Kenvue were worth $9,762,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of Kenvue during the 4th quarter valued at approximately $521,348,000. Starboard Value LP bought a new stake in Kenvue in the fourth quarter worth $467,864,000. Franklin Resources Inc. lifted its position in Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after buying an additional 10,682,003 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Kenvue by 3.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after buying an additional 8,211,748 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.1%

Shares of KVUE stock traded up $0.03 during trading hours on Wednesday, reaching $20.73. 15,607,303 shares of the company's stock were exchanged, compared to its average volume of 16,126,554. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $25.17. The stock has a market cap of $39.77 billion, a PE ratio of 37.69, a PEG ratio of 3.25 and a beta of 0.83. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The stock's fifty day moving average price is $22.51 and its two-hundred day moving average price is $22.31.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The company's revenue was down 3.9% on a year-over-year basis. Research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KVUE. Barclays raised their price target on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target for the company. Citigroup reiterated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Finally, UBS Group lifted their target price on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.